QL1706 With Olaparib for Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency (HRD)

Sponsor
The First Affiliated Hospital with Nanjing Medical University
Study ID
NCT07113964
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency

Eligibility Criteria

Sex
FEMALE
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • QL1706 + olaparib — DRUG
    QL1706 is a novel dual immune checkpoint blockade containing a mixture of anti-PD1 IgG4 and anti-CTLA4 IgG1 antibodies. Other Names: Iparomlimab and Tuvonralimab Injection Olaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor with biologic activity in ovarian cancer as well as other solid tumors.. Other Names: NA

Study Details

This study will evaluate the safety and efficacy of QL1706 and Olaparib in human epidermal growth factor receptor 2 (HER2)-negative unresectable and/or metastatic breast cancer who had received 2-4 line of prior systematic therapy.

Key Dates

Start date
Aug 30, 2025
Status verified
Jul 2025
Primary completion
Mar 30, 2027
Completion
Mar 30, 2029

Study Design

Enrollment
79 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Experimental:QL1706 + olaparib

Primary Outcome Measure

Progression-free Survival (PFS) [ Time Frame: Up to approximately 3 years ]

Central Contacts